Why Travere Therapeutics (TVTX) Is Up 18.9% After FDA Eases FILSPARI Oversight And Delays Adcom [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
FILSPARI, including the removal of an FDA advisory committee review and easing of REMS monitoring requirements ahead of a January 13, 2026 decision on a potential FSGS label expansion. This momentum highlights how FDA reaffirmation of proteinuria reduction as a key endpoint could influence FILSPARI's prospects in focal segmental glomerulosclerosis, an area with limited treatment options. We'll now examine how the upcoming FDA decision on FILSPARI's FSGS indication could reshape Travere's investment narrative and risk profile. This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality To own Travere Therapeutics, you need to believe FILSPARI can become a cornerstone therapy in rare kidney disease, especially if it secures an FSGS label. The latest FDA updates appear to support this near term by smoothing the review path and commercial use, but the January 13, 2026 FSGS decision remains the key catalyst and, given the missed
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday [Yahoo! Finance]Yahoo! Finance
- Is Travere Therapeutics Still Attractively Priced After Its 135% Share Price Surge? [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics (TVTX): Valuation Check After FDA Tailwinds and FSGS Expansion Hopes for FILSPARI [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TVTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Analyst Actions
- 11/28/25 - HC Wainwright
TVTX
Sec Filings
- 12/16/25 - Form 4
- 12/15/25 - Form 144
- 12/3/25 - Form 4
- TVTX's page on the SEC website